Having trouble viewing this email? View in your browser.

2 April 2019

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.


Registration for ECCMID 2019

ECCMID is approaching soon in Amsterdam!

Registrations are available at a reduced rate for ESCMID members on the official website.

Make sure you use our official website to book your hotels to get the best rates.

› Read more

ESCMID/EITaF Postgraduate course: Emerging infections for clinicians and the WHO Emerging Diseases Clinical Assessment and Response Network (EDCARN)

Don’t miss the upcoming ESCMID/EITaF  course on Emerging infections for clinicians in Florence, Italy, from 13-15 May 2019. This course will also include a day of workshop by the WHO Emerging Diseases Clinical Assessment and Response Network (EDCARN), simulating responses to an outbreak situation. 

› Read more

ECCMID on YouTube – Programme sneak peaks

Visit the ESCMID YouTube Channel to see interviews with members of the ECCMID 2019 Programme Committee, discussing the new developments that will be presented at ECCMID in Amsterdam.

Subscribe to the ESCMID channel to continue to receive updates before and during ECCMID!

› Read more

CMI highlight: Optimising antibiotic prescribing: Collective approaches to managing a common-pool resource

Piperaki et al. the review provides a brief overview of the important pharmacokinetic / pharmacocodynamic parameters of relevant antimicrobial agents, a critical evaluation of randomized controlled trials and observational studies, suggestions for increasing the strength of observational studies, and instructions to select treatment regimens according to the severity of the infection and the status of the host.

The authors aim: i) to assist physicians to adapt therapeutic approaches in CRAB infections by considering all potentially available antimicrobials and ii) to present directions for future investigations that emerge through treatment efforts in endemic settings.

Carbapenem-resistant Acinetobacter baumannii (CRAB) has gained global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated patients causing pneumonia and bloodstream infections with high mortality rates. Difficulties in treating CRAB infections stem from a formidable resistance profile that leaves available a few antibiotics of uncertain efficacy such as colistin and tigecycline. Despite the relentless attempts to improve therapeutic approaches (as depicted in colistin-oriented randomized clinical trials and the numerous observational studies), progress is still limited.

Articles and reviews from PubMed and Scopus databases; studies from ClinicalTrials.gov; presentations from ECCMID congresses and IDWeek meetings.

The lack of an optimal therapeutic regimen for CRAB thus far, as shown in this review, suggests the need to thoroughly investigate alternative approaches through carefully designed trials that should include all relevant drugs. Some of these alternative directions are indicated in the present review.

The absence of an optimal treatment regimen for CRAB so far, as this review shows, suggests the need to thoroughly investigate alternative approaches through carefully designed trials, which should include all relevant drugs. Some of these alternative orientations are indicated in Piperaki et al. review.

› Read more

TAE Trainees Day 2019 – Register Now!

Registration for TAE Trainees Day 2019 at ECCMID is already open and tables fill up fast! More than 50% of the places are already reserved and we urgently recommend to sign up now if you are interested in the TAE Day 2019.

Please find more information, the moderators’ CVs and registration for the TAE Day here

› Read more

"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children." Open for public consultation phase.

The draft version of the "ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children." has now entered into the public consultation phase. The guideline is a result of the concerted efforts of experts across Europe.

Those of you wishing to comment on the manuscript may write to the ESCMID Publications and Medical Guidelines Manager to request the (confidential) draft of the manuscript along with the comments form for listing feedback.

We are happy to receive your feedback and comments on the manuscript until 30th April 2019.

Please be aware that your comments and the authors’ responses to the comments will be made available online once the guideline is published.

Email: guidancedocuments@escmid.org  for a copy of the draft guideline!

› Read more

GARDP Webinar – 21 May 2019

Part 3 of GARDP’s series on Antibacterial drugs is occurring Tuesday 21 May!

The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. In this webinar, the development of antibacterial drug enhancer combinations and non-traditional products will be discussed.

The presentations will be followed by a Q&A session.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.